India Needs To Assure Regulation For Domestic Drugs
Express Pharma|August 16-31, 2019

While Indian pharma exports were regulated years ago, the time has come to start a new era for anti-counterfeiting domestic regulation. In a candid conversation, Nakul Pasricha, President, Authentication Solutions Providers Associations (ASPA), reveals more to Akanki Sharma

India Needs To Assure Regulation For Domestic Drugs

How often does the Indian pharma industry face the problem of falsified and sub-standard medicines?

According to a study by the International Institute of Research Against Counterfeit Medicines (IRACM), globally, counterfeiting has been measured as about $200 billion problem in terms of statistics. According to research from WHO study, an estimated one in 10 medical products circulating in low- and middle-income countries is either substandard or falsified. Since 2013, WHO has received 1,500 reports of cases of substandard or falsified products. Of these, antimalarials and antibiotics are the most commonly reported. Prior to 2013, there was no global reporting of this information and this is likely just a small fraction of the total problem and many cases may be going unreported. A regulation by the Director General of Foreign Trade (DGFT) has been there in our country since 2011, according to which all medicines exported out of India must have barcoding.

Solutions are available if f all stakeholders – regulators, pharma companies, solution providers and consumers – come together as one and resolve to stop the spread of spurious and sub-standard medicines

What are the adverse effects of these kinds of medicines on the economy of the country?

FICCI had done a study in 2015, where it was found that the loss of tax revenue is Rs 40,000 crores (excluding pharma). Unfortunately, the study did not include pharma sector. One way to estimate is that the total Indian pharmaceutical sector valued at US$ 35 billion in 2017. The domestic market of India is $17 billion. Some independent studies have found the rate of substandard or spurious drugs to be about seven to 10 percent in India. The country's pharmaceutical exports stood at US$ 17.27 billion in FY18 and have reached US$ 19.14 billion in FY19.

هذه القصة مأخوذة من طبعة August 16-31, 2019 من Express Pharma.

ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.

هذه القصة مأخوذة من طبعة August 16-31, 2019 من Express Pharma.

ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.

المزيد من القصص من EXPRESS PHARMA مشاهدة الكل
ACG covers every facet of the pharma process, all under one roof and seamlessly interconnected
Express Pharma

ACG covers every facet of the pharma process, all under one roof and seamlessly interconnected

ACG Inspection's Life Sciences Cloud will be making its India debut at the CPhI India- PMec India 2024 show. Udit Singh, CEO, ACG Inspection spoke to Viveka Roychowdhury on its USPs, highlighting its modular nature, the zero cost of transition from existing systems, and the advantage of ACG's long term partnerships with global standard setting organisations like GS1 which allow its platforms to deliver regulatory compliance deliverables in advance

time-read
4 mins  |
December 2024
We, at OmniActive, invest over 10 per cent of the total outlay into R&D
Express Pharma

We, at OmniActive, invest over 10 per cent of the total outlay into R&D

Sanjaya Mariwala, Executive Chairman and MD, OmniActive Health Technologies shares insights into the company's significant investments in R&D, advanced testing capabilities, and strategies for optimising bioactive ingredients. He also discusses the impact of regulatory changes, quality assurance, and consumer education in the evolving nutraceutical landscape, in an interview with Viveka Roychowdhury

time-read
3 mins  |
December 2024
Save coating time, boost production efficiency
Express Pharma

Save coating time, boost production efficiency

Instacoat 4G unique formulation includes an optimal ratio of polymer, plasticizer, and pigments, ensuring a smooth, uniform coating while significantly reducing preparation and process time

time-read
3 mins  |
December 2024
Pharma companies can optimise R&D budgets using advanced technologies
Express Pharma

Pharma companies can optimise R&D budgets using advanced technologies

Pharma companies can optimise their R&D budgets to maximise innovation and deliver high-value therapies by using combination of new technologies to enhance innovation, feed the drug-development pipeline and speed to market.

time-read
1 min  |
December 2024
The wide-ranging health benefits of Pycnogenol for women of all ages
Express Pharma

The wide-ranging health benefits of Pycnogenol for women of all ages

Dr Franziska Weichmann, Manager of Scientific Communications and Product Development at Horphag Research, highlights benefits of Pycnogenol, a French maritime pine bark extract, offering women across all life stages a natural way to manage the physical and emotional challenges tied to hormonal changes

time-read
10+ mins  |
December 2024
Indian pharma industry: Urgent need for action in the manufacturing sector
Express Pharma

Indian pharma industry: Urgent need for action in the manufacturing sector

Dr Ajay Babu Pazhayattil, President of cGMPWorld, offers invaluable insights from FDA Form 483 observations issued to Indian pharma facilities, shedding light on the industry's critical challenges today. His analysis provides immediate and practical plans to minimise regulatory compliance risks. These measures will help reinforce the Indian industry's commitment to supplying the much-needed lifesaving drug products for the regulated US market

time-read
10 mins  |
December 2024
Nutraceutical M&As: How strategic mergers are shaping the health and wellness market
Express Pharma

Nutraceutical M&As: How strategic mergers are shaping the health and wellness market

The nutraceutical industry has seen a surge in M&A activity over the past three years as companies pursue strategic acquisitions to strengthen market positions, diversify offerings, and drive innovation. Sudhindran N, GM - Corporate Affairs, Nutrify Today explores key trends, motivations, notable deals, and future growth prospects shaping the industry

time-read
3 mins  |
December 2024
Rising research costs, complex drug systems, stringent regulations, and global pressures pose major threats to pharma R&D
Express Pharma

Rising research costs, complex drug systems, stringent regulations, and global pressures pose major threats to pharma R&D

According to one of the published reports, the pharma industry invested about $83 billion in R&D in 2019, which is about 10 times the research and development (R&D) spent per year in the 1980s, after adjusting for the effects of inflation.

time-read
1 min  |
December 2024
Harnessing data analytics to propel drug discovery and development in 2025
Express Pharma

Harnessing data analytics to propel drug discovery and development in 2025

As the pharma landscape evolves, data analytics will be at the forefront of drug discovery and development, transforming traditional methods. By leveraging data-driven insights, companies can expedite R&D, optimise clinical trials, and personalise treatments, bringing life-saving therapies to market more efficiently, explains Biju Davis, SVP, Engineering, Model N

time-read
4 mins  |
December 2024
Strengthening our presence within APAC through increased penetration is a key focus
Express Pharma

Strengthening our presence within APAC through increased penetration is a key focus

Aanchal Tomar, Executive Director, Asia Pacific, Lonza Capsules Health Ingredients speaks about Lonza Capsules Health Ingredients’ strategic growth, challenges, and sustainability initiatives in the APAC market, showcasing their innovative capsule solutions and health ingredients that cater to the region's diverse pharmaceutical and nutraceutical needs, in an interview with Express Pharma

time-read
4 mins  |
December 2024